Results 181 to 190 of about 125,674 (260)

3D-QSAR Design of New Bcr-Abl Inhibitors Based on Purine Scaffold and Cytotoxicity Studies on CML Cell Lines Sensitive and Resistant to Imatinib. [PDF]

Pharmaceuticals (Basel)
Cabezas D, Delgado T, Sepúlveda G, Krňávková P, Vojáčková V, Kryštof V, Strnad M, Silva NI, Echeverría J, Espinosa-Bustos C, Mellado G, Luo J, Mella J, Salas CO.   +13 more
europepmc   +1 more source

BCR-ABL/GATA1/miR-138 mini circuitry contributes to the leukemogenesis of chronic myeloid leukemia

Oncogene, 2014
C. Xu, H. Fu, Liang Gao, Lu Wang, Wen Wang, Jingxin Li, Yan Li, L. Dou, Xiaoning Gao, Xin Luo, Y. Jing, Chim Cs, X. Zheng, Li Yu   +13 more
semanticscholar   +1 more source

BCR-ABL tyrosine kinase [PDF]

Science-Business eXchange, 2010
openaire   +1 more source

[Corrigendum] ND‑09 inhibits chronic myeloid leukemia K562 cell growth by regulating BCR‑ABL signaling. [PDF]

Oncol Rep
Liu YH, Zhu M, Lei PP, Pan XY, Ma WN.
europepmc   +1 more source

T cell receptors specific for an imatinib-induced mutation in BCR-ABL for adoptive T cell therapy. [PDF]

Front Immunol
Hsu MT, Willimsky G, Hansmann L, Blankenstein T.   +3 more
europepmc   +1 more source

Targeted Degradation of SOS1 Exhibits Potent Anticancer Activity and Overcomes Resistance in KRAS-Mutant Tumors and BCR-ABL-Positive Leukemia. [PDF]

Cancer Res
Luo Z, Lin C, Yu C, Yuan C, Wu W, Xu X, Sun R, Jia Y, Wang Y, Shen J, Wang D, Wang S, Jiang H, Jiang B, Yang X, Xie C.   +15 more
europepmc   +1 more source

BCR-ABL Peptide Vaccine [PDF]

, 2020
openaire   +1 more source

CDK8/19 inhibition attenuates G1 arrest induced by BCR-ABL antagonists and accelerates death of chronic myelogenous leukemia cells. [PDF]

Cell Death Discov
Khamidullina AI, Yastrebova MA, Bruter AV, Nuzhina JV, Vorobyeva NE, Khrustaleva AM, Varlamova EA, Tyakht AV, Abramenko IE, Ivanova ES, Zamkova MA, Li J, Lim CU, Chen M, Broude EV, Roninson IB, Shtil AA, Tatarskiy VV.   +17 more
europepmc   +1 more source

Co-Occurrence of Jak2-Positive Myelofibrosis and Bcr-Abl-Positive Chronic Myelogenous Leukaemia Treated with Combination of Tyrosine Kinase Inhibitors and Ruxolitinib. [PDF]

Mediterr J Hematol Infect Dis
Paciaroni K, Campagna S, Villiva N, Maffini E, Celesti F, Tordi A, Lombardi M, Dragonetti G, di Toritto TC.   +8 more
europepmc   +1 more source

Unveiling the nephrotoxic profile of BCR-ABL tyrosine kinase inhibitors: A real-world experience in Africa. [PDF]

EJHaem
Ayalew ZS, Azibte GT, Tadesse F, Legesse BA, Kiflu ZG, Weldeamanuel MT, Tsige KA, Molla BA, Ejigu AM.   +8 more
europepmc   +1 more source